340B Snapshot: Janssen's Discounts In US Program Have Risen 220% Over Past Five Years
Executive Summary
Janssen's 2021 US price transparency report offers insights into why the company recently joined the growing number of major pharma manufacturers who are restricting 340B discounts to contract pharmacies participating in the program.
You may also be interested in...
340B Program Spending Continues To Swell In 2022, Topping $53bn
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.
Janssen 340B Discount Growth Slowed In 2022 But Still Topped $6bn; Patient Assistance Jumps 24%
Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.
340B Better Together? PhRMA Partners With Community Health Centers On Legislative Reforms
PhRMA's collaboration with the provider group may help alleviate concerns that legislators' pursuit of pharma-backed 340B reforms would pit lawmakers against hospitals that serve as a safety net for vulnerable patients.